Analysts' ratings for Neurocrine Biosciences NBIX over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 5 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 6 | 2 | 1 | 0 | 0 |
| 2M Ago | 1 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average reflects an increase of 0.47% from the previous average price target of $168.60.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Neurocrine Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $185.00 | $185.00 |
| Yatin Suneja | Guggenheim | Lowers | Buy | $163.00 | $165.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $185.00 | $190.00 |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $148.00 | $154.00 |
| Laura Chico | Wedbush | Lowers | Outperform | $147.00 | $157.00 |
| Sumant Kulkarni | Canaccord Genuity | Lowers | Buy | $163.00 | $172.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $185.00 | $190.00 |
| Tazeen Ahmad | B of A Securities | Lowers | Buy | $179.00 | $184.00 |
| Jeffrey Hung | Morgan Stanley | Raises | Overweight | $185.00 | $170.00 |
| Ashwani Verma | UBS | Raises | Buy | $176.00 | $162.00 |
| Ashwani Verma | UBS | Raises | Buy | $162.00 | $142.00 |
| David Amsellem | Piper Sandler | Maintains | Overweight | $160.00 | $160.00 |
| Carter Gould | Barclays | Raises | Overweight | $165.00 | $160.00 |
| Laura Chico | Wedbush | Maintains | Outperform | $148.00 | $148.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.
Capture valuable insights into Neurocrine Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Delving into Neurocrine Biosciences's Background
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Understanding the Numbers: Neurocrine Biosciences's Finances
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin excels beyond industry benchmarks, reaching 16.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 3.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA excels beyond industry benchmarks, reaching 2.84%. This signifies efficient management of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
